Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model

F. Favreau, R. Thuillier, J. Cau, S. Milin, E. Manguy, G. Mauco, X. Zhu, Lilach O Lerman, T. Hauet

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Ischemia reperfusion injury (IRI) is pivotal for renal fibrosis development via peritubular capillaries injury. Coagulation represents a key mechanism involved in this process. Melagatran® (M), a thrombin inhibitor, was evaluated in an autotransplanted kidney model, using Large White pigs. To mimic deceased after cardiac death donor conditions, kidneys underwent warm ischemia (WI) for 60 min before cold preservation for 24 h in University of Wisconsin solution. Treatment with M before WI and/or in the preservation solution drastically improved survival at 3 months, reduced renal dysfunction related to a critical reduction in interstitial fibrosis, measured by Sirius Red staining. Tissue analysis revealed reduced expression of transforming growth factor-β (TGF-β) and activation level of its effectors phospho-Smad3, Smad4 and connective tissue growth factor (CTGF) after M treatment. Fibrinolysis activation was also observed, evidenced by downregulation of PAI-1 protein and gene expression. In addition, M reduced S100A4 expression and vimentin staining, which are markers for epithelial mesenchymal transition, a major pathway to chronic kidney fibrosis. Finally, expression of oxidative stress markers Nox2 and iNOS was reduced. We conclude that inhibition of thrombin is an effective therapy against IRI that reduces chronic graft fibrosis, with a significantly positive effect on survival.

Original languageEnglish (US)
Pages (from-to)30-39
Number of pages10
JournalAmerican Journal of Transplantation
Volume10
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Warm Ischemia
Thrombin
Fibrosis
Transplants
Kidney
Reperfusion Injury
Staining and Labeling
Connective Tissue Growth Factor
Therapeutics
Epithelial-Mesenchymal Transition
Plasminogen Activator Inhibitor 1
Transforming Growth Factors
Fibrinolysis
Vimentin
Oxidative Stress
Swine
Down-Regulation
dicarboxydine
Gene Expression
Wounds and Injuries

Keywords

  • Direct thrombin inhibitor
  • Graft function
  • Interstitial fibrosis/tubular atrophy
  • Ischemia reperfusion injury
  • Kidney preservation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. / Favreau, F.; Thuillier, R.; Cau, J.; Milin, S.; Manguy, E.; Mauco, G.; Zhu, X.; Lerman, Lilach O; Hauet, T.

In: American Journal of Transplantation, Vol. 10, No. 1, 01.2010, p. 30-39.

Research output: Contribution to journalArticle

Favreau, F. ; Thuillier, R. ; Cau, J. ; Milin, S. ; Manguy, E. ; Mauco, G. ; Zhu, X. ; Lerman, Lilach O ; Hauet, T. / Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. In: American Journal of Transplantation. 2010 ; Vol. 10, No. 1. pp. 30-39.
@article{b5815a0f6f3c4a50b45fbe28a8b40eee,
title = "Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model",
abstract = "Ischemia reperfusion injury (IRI) is pivotal for renal fibrosis development via peritubular capillaries injury. Coagulation represents a key mechanism involved in this process. Melagatran{\circledR} (M), a thrombin inhibitor, was evaluated in an autotransplanted kidney model, using Large White pigs. To mimic deceased after cardiac death donor conditions, kidneys underwent warm ischemia (WI) for 60 min before cold preservation for 24 h in University of Wisconsin solution. Treatment with M before WI and/or in the preservation solution drastically improved survival at 3 months, reduced renal dysfunction related to a critical reduction in interstitial fibrosis, measured by Sirius Red staining. Tissue analysis revealed reduced expression of transforming growth factor-β (TGF-β) and activation level of its effectors phospho-Smad3, Smad4 and connective tissue growth factor (CTGF) after M treatment. Fibrinolysis activation was also observed, evidenced by downregulation of PAI-1 protein and gene expression. In addition, M reduced S100A4 expression and vimentin staining, which are markers for epithelial mesenchymal transition, a major pathway to chronic kidney fibrosis. Finally, expression of oxidative stress markers Nox2 and iNOS was reduced. We conclude that inhibition of thrombin is an effective therapy against IRI that reduces chronic graft fibrosis, with a significantly positive effect on survival.",
keywords = "Direct thrombin inhibitor, Graft function, Interstitial fibrosis/tubular atrophy, Ischemia reperfusion injury, Kidney preservation",
author = "F. Favreau and R. Thuillier and J. Cau and S. Milin and E. Manguy and G. Mauco and X. Zhu and Lerman, {Lilach O} and T. Hauet",
year = "2010",
month = "1",
doi = "10.1111/j.1600-6143.2009.02924.x",
language = "English (US)",
volume = "10",
pages = "30--39",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model

AU - Favreau, F.

AU - Thuillier, R.

AU - Cau, J.

AU - Milin, S.

AU - Manguy, E.

AU - Mauco, G.

AU - Zhu, X.

AU - Lerman, Lilach O

AU - Hauet, T.

PY - 2010/1

Y1 - 2010/1

N2 - Ischemia reperfusion injury (IRI) is pivotal for renal fibrosis development via peritubular capillaries injury. Coagulation represents a key mechanism involved in this process. Melagatran® (M), a thrombin inhibitor, was evaluated in an autotransplanted kidney model, using Large White pigs. To mimic deceased after cardiac death donor conditions, kidneys underwent warm ischemia (WI) for 60 min before cold preservation for 24 h in University of Wisconsin solution. Treatment with M before WI and/or in the preservation solution drastically improved survival at 3 months, reduced renal dysfunction related to a critical reduction in interstitial fibrosis, measured by Sirius Red staining. Tissue analysis revealed reduced expression of transforming growth factor-β (TGF-β) and activation level of its effectors phospho-Smad3, Smad4 and connective tissue growth factor (CTGF) after M treatment. Fibrinolysis activation was also observed, evidenced by downregulation of PAI-1 protein and gene expression. In addition, M reduced S100A4 expression and vimentin staining, which are markers for epithelial mesenchymal transition, a major pathway to chronic kidney fibrosis. Finally, expression of oxidative stress markers Nox2 and iNOS was reduced. We conclude that inhibition of thrombin is an effective therapy against IRI that reduces chronic graft fibrosis, with a significantly positive effect on survival.

AB - Ischemia reperfusion injury (IRI) is pivotal for renal fibrosis development via peritubular capillaries injury. Coagulation represents a key mechanism involved in this process. Melagatran® (M), a thrombin inhibitor, was evaluated in an autotransplanted kidney model, using Large White pigs. To mimic deceased after cardiac death donor conditions, kidneys underwent warm ischemia (WI) for 60 min before cold preservation for 24 h in University of Wisconsin solution. Treatment with M before WI and/or in the preservation solution drastically improved survival at 3 months, reduced renal dysfunction related to a critical reduction in interstitial fibrosis, measured by Sirius Red staining. Tissue analysis revealed reduced expression of transforming growth factor-β (TGF-β) and activation level of its effectors phospho-Smad3, Smad4 and connective tissue growth factor (CTGF) after M treatment. Fibrinolysis activation was also observed, evidenced by downregulation of PAI-1 protein and gene expression. In addition, M reduced S100A4 expression and vimentin staining, which are markers for epithelial mesenchymal transition, a major pathway to chronic kidney fibrosis. Finally, expression of oxidative stress markers Nox2 and iNOS was reduced. We conclude that inhibition of thrombin is an effective therapy against IRI that reduces chronic graft fibrosis, with a significantly positive effect on survival.

KW - Direct thrombin inhibitor

KW - Graft function

KW - Interstitial fibrosis/tubular atrophy

KW - Ischemia reperfusion injury

KW - Kidney preservation

UR - http://www.scopus.com/inward/record.url?scp=72549112632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549112632&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02924.x

DO - 10.1111/j.1600-6143.2009.02924.x

M3 - Article

C2 - 19958330

AN - SCOPUS:72549112632

VL - 10

SP - 30

EP - 39

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -